SCHEDULE: BlackRock Boosts NeoGenomics Stake to 14.6%
Beneficial Ownership Report
BlackRock, Inc. has filed an Amendment No. 4 to Schedule 13G, reporting a 14.6% beneficial ownership stake in NeoGenomics Inc. as of September 30, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 18,861,974 shares of NeoGenomics Inc. common stock.
- This represents 14.6% of the total outstanding common stock.
- BlackRock holds sole voting power over 18,561,116 shares and sole dispositive power over 18,861,974 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of NeoGenomics Inc.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., beneficially owns 5% or greater of the outstanding shares.
- iShares Core S&P Small-Cap ETF is also known to have an interest exceeding 5% in NeoGenomics Inc. common stock.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a routine disclosure of beneficial ownership and typically has a neutral sentiment, indicating standard institutional investment activity without implying positive or negative operational performance.
Positives
- Increased institutional ownership by a major asset manager like BlackRock can signal confidence in the company's long-term prospects.
- The filing confirms BlackRock's passive investment intent, indicating no immediate plans to influence company control.
Management Comments
- I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.
Industry Context
BlackRock, as one of the world's largest asset managers, routinely files Schedule 13G reports to disclose its passive ownership stakes in public companies across various sectors, including healthcare and diagnostics. This filing reflects its ongoing portfolio management activities and its significant presence in the market, consistent with its role as a major institutional investor.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Authorized Signatories for SEC Filings (BlackRock, Inc.) | Various individuals under the April 30, 2023 Power of Attorney | Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg, Brenda Schulz | 2025-01-21 | Update and revocation of previous Power of Attorney to authorize a new list of individuals for executing and filing ownership or control-person reporting requirements. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. updated its Power of Attorney, authorizing a new list of individuals to execute and file ownership or control-person reporting requirements with regulatory authorities. | 2025-01-21 | Streamlines the process for BlackRock's internal compliance and SEC filing procedures, ensuring proper authorization for disclosure documents. |
Stakeholder Impact
- Shareholders: Increased institutional ownership by BlackRock may be viewed positively as a sign of confidence, potentially enhancing liquidity and stability.
- Management: Awareness of a significant institutional holder like BlackRock, though passive, can influence strategic considerations.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous Power of Attorney, which was subsequently revoked, was dated. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. signatories. |
| 2025-09-30 | Date of event which requires filing of this statement, reflecting BlackRock's beneficial ownership. |
| 2025-10-17 | Date of filing and signature by BlackRock, Inc. |
Keywords
NeoGenomics, BlackRock, Institutional Ownership, Schedule 13G, Common Stock, Investment, Asset Management, Healthcare, Diagnostics
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.